anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Small bowel obstruction is a major source of morbidity and mortality that carries a significant economic burden. Recurrent small bowel obstruction may be secondary to circumferential strictures (small bowel diaphragm disease), an under-recognized entity secondary to long-term nonsteroidal anti-inflammatory drug (NSAID) use. We aimed to describe the sensitivity of preoperative computed tomography (CT) enterography in patients with surgically treated small bowel diaphragm disease.
METHODS: We retrospectively reviewed adult patients who underwent elective small bowel resection for small bowel obstruction performed by a single minimally invasive surgeon between 2010 and 2023. Patient history, radiographic, endoscopic, operative, and pathology reports were reviewed for reference to NSAID use, small bowel strictures, diaphragms, and enteropathy. Exclusion criteria were prior radiation, inflammatory bowel disease, malignancy, adhesive disease, and anastomotic strictures.
RESULTS: A total of 225 patients were identified, 22 (10%) of whom met the inclusion criteria. The mean age was 60.7 years (range 29-78), with 15 women (68%). All patients underwent minimally invasive small bowel resection for obstruction with histopathologic evidence of stricture without evidence of transmural inflammation, granuloma, or dysplasia and confirmed NSAID use (n = 22, 100%). Anemia was present in 36% (n = 8). Preoperative CT or magnetic resonance (MR) enterography was performed in 18 patients (82%), of which stricturing was reported in 13 (72%). Intraoperatively, palpation identified strictures in all patients.
CONCLUSION: NSAID-induced small bowel injury is an under-recognized condition that, in severe cases, can present as small bowel obstruction. Surgeons should consider diaphragm disease in patients with obstruction and NSAID use, in which preoperative CT or MR enterography may be useful but cannot rule out disease.
Control patients (n=20): In individuals undergoing vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc), a piece of healthy vessel must sometimes be removed in order to facilitate the surgical process. The vessel biopsies from this group will be categorized as "healthy vessels" in our study.
The invention relates to a traditional Chinese medicine composition for effectively treating gastrocnemius spasm, and a preparation method and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-18 parts of pawpaw, 30-60 parts of herba epimedii, 20-40 parts of lycopodium clavatum, 15-30 parts of fructus evodiae, 10-30 parts of caulis spatholobi, 10-20 parts of radix achyranthis bidentatae and 4-10 parts of raw liquorice. The invention also comprises a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparing a medicine for treating gastrocnemius spasm. Its advantages are: 1. the invention optimizes the raw materials, and the raw materials accord with the compatibility principle of monarch, minister, assistant and guide and act synergistically. 2. The ratio of the raw materials is screened by tests, and the effect is obvious. 3. The raw materials have wide sources, the preparation method is simple and convenient, the medicine with corresponding dosage forms can be prepared by adjusting according to the acceptable degree of patients, the acceptability of the patients is improved, the curative effect is good, and the practicability is very strong.
Since whey powder contains 73.45 grams of carbohydrate per 100 grams, whey was given to the patients in this study, unlike OCS (Oral Carbohydrate Solution), as it met the requirement in the ERAS protocol that at least 45 g of oral carbohydrate solution can be given two hours before surgery. It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink. Before the surgery, the patients' hunger, thirst, blood glucose and nausea and vomiting levels were evaluated.
The Rural Alaska Community Action Program (RurAL CAP), which administers Head Start schools in rural Alaska, reports that 68% of Alaska Native children ages 3 to 5 years are overweight and 43% are obese. Diet, physical activity, and sleep hygiene are primary risk factors for childhood obesity, a risk factor for cardiometabolic diseases later in life. Notably, subclinical cardiovascular pathology can be detected as early as 3 years of age. Once living off the land and sea, Alaska Native (AN) people have suffered decades of colonization and in-migration, which have interfered with traditional food consumption, signaling a striking change in local food systems. Diet and physical activity are prime targets for early intervention, as taste preferences and exercise habits established in childhood forge lifelong adherence. Thus, investigators have designed More Outside Your Door, a multilevel intervention, which at the individual level builds on prior efforts to promote traditional diet and activities to decrease risk for obesity in Alaska Native preschoolers. At the family level, MOYD provides feedback to parents about their child's health screenings; at the school level, it features traditional foods, outdoor traditional physical activities, and a culturally centered curriculum. At the community level, it offers resources to improve the built environment for safe outdoor play that invites all community members to participate. In partnership, the Alaska Native Tribal Health Consortium, RurAL CAP, and collaborators will refine and test the effectiveness of MOYD at 12 Head Start preschools in the Yukon-Kuskokwim region: (1) investigators will use qualitative methods with Head Start staff, parents, and community Elders to optimally tailor MOYD for southwest Alaska communities; (2) investigators will conduct a stepped-wedge group-randomized trial to test its effect on children's diet, physical activity (PA), body mass index (BMI), and other risk factors for obesity-related chronic disease over three years. Primary outcomes are diet (classroom meals, actigraphy-based physical activity, and body mass index. Secondary outcomes include individual child level measures of hemoglobin levels and educational and developmental progress; parent report of diet, activity, and sleep at home; and measures of traditional foods/sugar-sweetened/processed foods by carbon and nitrogen stable isotope ratios using fingernail clippings. Investigators will also measure outcomes at the school level (classroom meals, outdoor time) and community level (objective data on use of play space). (3) Investigators will conduct a process evaluation using the RE-AIM framework. The Specific Aims are to (1) conduct preschool staff and parent/elder workgroups to refine the MOYD intervention for optimal effectiveness for obesity prevention among AN preschool children; (2) test the effectiveness of MOYD on a) diet, PA, outdoor time, and BMI; and b) improving other clinical and behavioral risk factors for obesity-related chronic disease in preschool children; and (3) Implement the RE-AIM framework to evaluate dissemination and implementation of the MOYD intervention in Head Start programs.
FIELD: medical equipment.SUBSTANCE: sensor device for helping a person providing assistance in cardiopulmonary resuscitation of a patient suffering from cardiac arrest contains a means of attachment for attaching the sensor device to the patient’s chest, a motion sensor and an interface for sending and/or receiving data and/or commands. The sensor device additionally contains a flat and waterproof main case part, which includes a motion sensor, an electrical energy storage device, a processor and an interface. The main case part contains the upper side, which is touched by the hand of the assisting person during the targeted use of the sensor device, and the lower side, which is touched by the chest of the patient during the targeted use of the sensor device. The sensor device additionally contains a positioning device for precise positioning of the sensor device on the patient’s chest. The positioning device is a measuring standard, which is made extendable from the main case part. Adhesive coating is located on the surface of the upper side of the main case part. The use of a sensor device according to one of the preceding points for analyzing the sequence of movements of a living being is disclosed.EFFECT: providing a simple and easy-to-use sensor device for providing data when performing first aid measures during resuscitation of a person suffered from cardiac arrest.14 cl, 1 dwg
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has occurred with Epitol. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. This disorder is variable in its expression, and other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Epitol should be discontinued if an alternative etiology for the signs or symptoms cannot be established.

###  Hypersensitivity

Hypersensitivity reactions to carbamazepine have been reported in patients who previously experienced this reaction to anticonvulsants including phenytoin, primidone, and phenobarbital. If such history is present, benefits and risks should be carefully considered and, if carbamazepine is initiated, the signs and symptoms of hypersensitivity should be carefully monitored. 

Patients should be informed that about a third of patients who have had hypersensitivity reactions to carbamazepine also experience hypersensitivity reactions with oxcarbazepine (Trileptal®).

###  Anaphylaxis and Angioedema

Rare cases of anaphylaxis and angioedema involving the larynx, glottis, lips, and eyelids have been reported in patients after taking the first or subsequent doses of Epitol. Angioedema associated with laryngeal edema can be fatal. If a patient develops any of these reactions after treatment with Epitol, the drug should be discontinued and an alternative treatment started. These patients should not be rechallenged with the drug.
Seventy to ninety-eight percent of obese children become obese adults. Comorbidities of obesity such as type II diabetes, fatty liver disease, hyperlipidemia, hypertension, asthma, sleep apnea, and depression are becoming increasing common in adolescents as more adolescents become obese. The only consistently durable and effective weight loss programs for the morbidly obese patients are those that include bariatric surgical procedures. The investigators believe that the best initial bariatric surgical option for adolescents is LAGB because of its low complication rates, adjustability, and reversibility. Obese adolescents ages 14-17 who meet criteria for entry will be enrolled to determine the degree of success of LAGB as measured by % excess weight loss, decreased % body fat, decreased body mass index (BMI), reduction in comorbid conditions, and metabolic parameters (including serum lipids and glucose tolerance) at intervals of 3 months, 6 months, 1 year, then annually for a total of 5 years postoperatively. Eligible patients will have been followed for 6 months by physicians in the Center for Adolescent Bariatric Surgery and: 1) will attended a minimum of 75% of visits and 2) will have failed to lose at least 20% of excess weight. Following evaluation by the team (which will include evaluations by a nutritionist, an endocrinologist, a psychologist/psychiatrist, a pediatric nurse practitioner, and a surgeon) a patient may be offered LAGB.
<P>PROBLEM TO BE SOLVED: To provide a method and composition for in vivo and in vitro targeting.  <P>SOLUTION: A large number of targeting peptides directed towards human organs, tissues, or cell types are disclosed. A novel class of gene therapy vectors is useful for targeted delivery of therapeutic agents including but not limited to gene therapy vectors. Certain of the disclosed peptides are therapeutically used for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy, or inducing weight loss. The composition is applied for identifying novel targeting peptides in humans, identifying endogenous receptor-ligand pairs, identifying novel infectious agents that are causal for human disease states, as well as inducing apoptosis.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The invention provides a preparation method of a human oligodendrocyte precursor cell inhibiting nerve secondary. Specifically, the method includes: constructing a virus expression vector of two glial growth factors, conducting cotransfection of a human oligodendrocyte precursor cell to prepare the human oligodendrocyte precursor cell, which can achieve high expression of the two glial growth factors, i.e. a growth related factor 43 and a glial growth factor 2, give play to the combined action of the two to promote oligodendrocyte repair, and inhibit nerve secondary injury caused by proliferative response and glial scar formation after oligodendrocyte injury. Also, the proliferation and differentiation ability of oligodendrocyte precursor cell itself is also utilized to participate in nerve function repair, and no tumorigenesis exists. The invention also provides a kit for preparation of the human oligodendrocyte precursor cell inhibiting nerve secondary. The human oligodendrocyte precursor cell provided by the invention has very good therapeutic effect on nervous system diseases.
Cosmetic composition comprising 2-10% of a mixture of proteolytic and lipolytic enzymes in ratio of 1:10 to 1:30 together with a carrier having a pH of 7 to 8. Treatment of defective fat metabolism in the epidermis and improve the skin appearance. Preferred enzymes are pancreatic proteases and lipases. A cosmetic mask comprised 5% of an enzyme mixture and 95% of CaCO3 or bentonite. The dry base was mixed with an equal proportion of 50% aq. glycerol contng. 1% of CMC.
PURPOSE:To obtain an antitumor agent having life-prolonging effect by the immuno-activation activity to macrophage, etc., and cancer cell proliferation suppressing effect and effective on man and animal, by using treated cell of mycoplasma as an active component. CONSTITUTION:The objective antitumor agent contains treated cell of mycoplasma (Mycoplasma gallisepticum, Mycoplasma hyorhinis and/or Mycoplasma orale, etc.) as an active component. A remarkable antitumor effect can be attained by sunergistic effect by adding an interferon (e.g. interferon alphaand/or interferon gamma) as the 2nd active component to the above antitumor agent. Mycoplasma can be produced according to conventional process e.g. by the stationary culture in a liquid medium produced by adding a serum of cattle, horse, pig, etc., or yeast extract to a general PPLO medium, etc., by conventional method.
Recruitment of diagnosed patients with PA from multiple centers, confirmation of subject eligibility according to inclusion criteria and exclusion criteria, and signing of informed consent forms. All eligible subjects enter a 2-week enrollment phase and only take stable doses of controlled-release nifedipine. After completing baseline examinations, subjects with SBP \<180 and ≥140 mmHg and DBP \<120 and ≥90 mmHg enter the follow-up phase of the treatment period. Eligible subjects receive a starting dose of 20 mg qd of Finerenone. If the blood pressure is still ≥140/90 mmHg at week 4, serum potassium is \<5.0 mmol/L, and eGFR has decreased \<30% compared to baseline, the Finerenone dose is adjusted to 40 mg qd.
Guided audio of placebo HVBR pre-recorded by a trained breathwork facilitator for \~20min/day over 21 days (three weeks). Delivered remotely through audio link, comprising music and four rounds of paced breathing at 15b/min (equal inhale:exhale) with four separate brief retentions, progressively increasing in length (from \~10secs to \~25secs).
The study is a follow up of NCT01844362. Uterus transplantation will be performed from live donors to patients with uterine factor infertility. If will be performed before transplantation. Organ procurement from the donor will be performed by robotic assisted laparoscopy. Transplantation will be by laparotomy. Embryo transfer will be done 10-12 months after transplantation. After birth of 1-3 children the uterus will be removed by hysterectomy.
In Parkinson's disease (PD) patients undergoing standard-of-care Deep Brain Stimulation (DBS) therapy, to compare the effect on Parkinson's symptoms of two different neurostimulator settings designed to differ from each other as much as possible with respect to how much they activate two different neuroanatomical structures: the axonal pathway from Globus Pallidus (GP) to Pedunculopontine Nucleus (PPN), and the axonal pathway from PPN to GP. In this respect, the present protocol is similar to Protocol STUDY00008644. In fact, that protocol, and this one, cover different Aims of the same NIH-funded project. Protocol STUDY00008644 tested different neurostimulor settings for a few hours in the laboratory only; the present protocol also tests them for two weeks between laboratory testing sessions. This is essential, for several reasons. First, clinically relevant outcome measures, such as ADL (activities of dailly life) and QOL (quality of life) scales require observation for longer than a few hours in the laboratory. Second, DBS effects are not instantaneous, and prolonged observation is required to determine the full effect of neurostimulator settings. Third, we intend, if our hypothesis is confirmed (that activation of the PPN-to-GP pathway is most effective for the postural-instability / gait-disorder (PIGD) complex) to propose a clinical trial of neurostimulator settings designed to maximize activation of this pathway; the present protocol will yield data and experience essential for designing and proposing such a trial.
In Wait list, participants will be asked to go about their life as usual. They will be asked not to participate in any other programs for PTSD or depression symptoms for 10 weeks. After the 10 weeks, WL participants can begin any other program for PTSD or depression. They will also be given the option of participating in BPS webSTAIR or be provided with information about other web-based programs that might be of interest or relevant to them.
Previous studies of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein-mediated membrane fusion have focused on laboratory-adapted T-lymphotropic strains of the virus. The goal of this application was to develop a novel screening assay to characterize membrane fusion mediated by a primary HIV-1 isolate in comparison with a laboratory-adapted strain. To this end, a novel fusion assay was developed on the basis of the principle of resonance energy transfer, using HeLa cells stably transfected with gp120/gp41 from the T-lymphotropic isolate HIV-1 LA1  or the macrophage-tropic primary isolate HIV-1 JR-FL . These cells fused with CD4 +  target cell lines with a tropism mirroring that of infection by the two viruses. Of particular note, HeLa cells expressing HIV-1 JR-FL  gp120/gp41 fused only with PM1 cells, a clonal derivative of HUT 78, and not with other T-cell or macrophage cell lines. These results demonstrate that the envelope glycoproteins of these strains play a major role in mediating viral tropism. Despite significant differences exhibited by HIV-1 JR-FL  and HIV-1 LAI  in terms of tropism and sensitivity to neutralization by CD4-based proteins, the present study found that membrane fusion mediated by the envelope glycoproteins of these viruses had remarkably similar properties. In particular, the degree and kinetics of membrane fusion were similar, fusion occurred at neutral pH and was dependent on the presence of divalent cations. The claimed invention will facilitate the screening and identification of novel agents that are capable of inhibiting these interactions.
The causality in the association between cannabis use and the risk of developing schizophrenia has been the subject of intense debate in the last few years. The development of animal models recapitulating several aspects of the disease is crucial for shedding light on this issue. Given that maternal infections are a known risk for schizophrenia, here, we used the maternal immune activation (MIA) model combined with THC exposure during adolescence to examine several behaviours in rats (working memory in the Y maze, sociability in the three-chamber test, sucrose preference as a measure, prepulse inhibition and formation of incidental associations) that are similar to the different symptom clusters of the disease. To this end, we administered LPS to pregnant dams and when the offspring reached adolescence, we exposed them to a mild dose of THC to examine their behaviour in adulthood. We also studied several parameters in the dams, including locomotor activity in the open field, elevated plus maze performance and their response to LPS, that could predict symptom severity of the offspring, but found no evidence of any predictive value of these variables. In the adult offspring, MIA was associated with impaired working memory and sensorimotor gating, but surprisingly, it increased sociability, social novelty and sucrose preference. THC, on its own, impaired sociability and social memory, but there were no interactions between MIA and THC exposure. These results suggest that, in this model, THC during adolescence does not trigger or aggravate symptoms related to schizophrenia in rats.
In one embodiment, a method of performing a structured collection protocol by utilizing a collection device comprising a processor may include collecting at least one sample using the collection device. The at least one sample can be associated with biomarker data. A classification can be associated with the at least one sample via the processor. The classification can be based upon an intended use of the at least one sample. Compliance with an adherence criteria for the at least one sample can be determined via the processor. When the at least one sample is not compliant with the adherence criteria, an adherence event can be associated with the at least one sample, and the processor can perform at least one additional task that is based upon the classification associated with the at least one sample.
Disease: Resected AJCC stage 3 or 4 melanoma. Anti-PD-1 monotherapy (Nivolumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.